Why the study?
Does levosimendan reduce mortality and need for RRT in high-risk cardiac surgery patients with LVEF ≤ 35% and/or LCOS?
Does levosimendan reduce mortality and need for RRT in high-risk cardiac surgery patients with LVEF ≤ 35% and/or LCOS?
Levosimendan reduces mortality in patients with preoperative severely reduced LVEF and reduces the need for RRT after high-risk cardiac surgery, though it does not affect overall mortality in the broader high-risk population.
No takes yet. Share an insight, caveat, or question.
Supports levosimendan in LVEF <35% high-risk surgery to cut mortality and RRT; extends Level 1 evidence for targeted use.
Sanfilippo et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: